Invesaro

Stocks Industrials LAB

NASDAQ · Industrials

Standard Biotools Inc. (LAB)

Standard Biotools Inc. brought in $84.6M of revenue over the twelve months to June 30, 2026, up 30.2% from a year earlier. Net income was $84.9M, a net margin of 100.4%. In fiscal 2025 capital spending exceeded operating cash flow by $82.6M. At June 30, 2026 it held $270M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

Price
$0.74
-0.42% on the day · September 25, 2026
52-week range $0.63 to $1.72
Market cap
$290.5M
Revenue (last 12 months)
$84.6M
+30.2% year on year
Net margin
100.4%

What Standard Biotools Inc. does

Standard Biotools Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LAB.

Revenue and profit by year

Revenue
FY18: $113M $113M FY18FY19: $117.2M $117.2M FY19FY20: $138.1M $138.1M FY20FY21: $130.6M $130.6M FY21FY22: $97.9M $97.9M FY22FY23: $106.3M $106.3M FY23FY24: $91M $91M FY24FY25: $85.3M $85.3M FY25
Net income
FY18: -$59M -$59M FY18FY19: -$64.8M -$64.8M FY19FY20: -$53M -$53M FY20FY21: -$59.2M -$59.2M FY21FY22: -$190.1M -$190.1M FY22FY23: -$74.7M -$74.7M FY23FY24: -$138.9M -$138.9M FY24FY25: -$74.9M -$74.9M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$85.3M-$110.2M-$74.9M-$0.20-$82.6M
2024$91M-$127.5M-$138.9M-$0.52-$151.8M
2023$106.3M-$76.6M-$74.7M-$0.94-$46.1M
2022$97.9M-$116.2M-$190.1M-$2.43-$93.2M
2021$130.6M-$67.5M-$59.2M-$0.78-$57.3M
2020$138.1M-$51M-$53M-$0.74-$28.1M

Latest SEC filings

What Standard Biotools Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 9, 2026
  2. August 14, 2026
  3. August 14, 2026
  4. August 5, 2026
  5. August 5, 2026
  6. August 5, 2026
    Quarterly report 10-Q · period to June 30, 2026
  7. August 5, 2026
  8. July 30, 2026
  9. July 29, 2026
  10. July 29, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 24, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about LAB

What does Standard Biotools Inc. do?

Standard Biotools Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LAB.

Is Standard Biotools Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $84.9M on revenue of $84.6M, a net margin of 100.4%.

How much revenue does Standard Biotools Inc. make?

Over the twelve months to June 30, 2026 Standard Biotools Inc. reported revenue of $84.6M. That is 30.2% more than a year earlier.

When did Standard Biotools Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the merger registration (amended) from September 9, 2026.

Similar companies

Follow LAB

Get an email when Standard Biotools Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow LAB: get an email when it files

Where the numbers come from

Financial figures are the values Standard Biotools Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.